<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691349</url>
  </required_header>
  <id_info>
    <org_study_id>PG-CART-01</org_study_id>
    <nct_id>NCT04691349</nct_id>
  </id_info>
  <brief_title>CAR-T for r/r Malignant Tumors in Children</brief_title>
  <official_title>Chimeric Antigen Receptor T Cells Therapy for r/r Malignant Tumors in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical study of CAR-T treatment of patients with relapsed/refractory&#xD;
      malignant tumors in children. The purpose is to evaluate the safety and effectiveness of&#xD;
      chimeric antigen receptor T cells in the treatment of relapsed/refractory malignant tumors in&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2020</start_date>
  <completion_date type="Anticipated">September 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR3</measure>
    <time_frame>Three months after CAR T cell infusion</time_frame>
    <description>3-month objective response rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>CAR-T</condition>
  <condition>Child, Only</condition>
  <condition>Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>Chimeric antigen receptor T cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR-T</intervention_name>
    <description>The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.</description>
    <arm_group_label>Chimeric antigen receptor T cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 3-18&#xD;
&#xD;
          -  Expected survival time ≥ 12weeks&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  At least second-line or above chemotherapy failed&#xD;
&#xD;
          -  Liver and kidney function, heart and lung function meet the following requirements:&#xD;
&#xD;
        Creatinine is within the normal range; Left ventricular ejection fraction ≥ 45%; Baseline&#xD;
        blood oxygen saturation&gt;91%; Total bilirubin≤1.5×ULN; ALT and AST≤2.5×ULN&#xD;
&#xD;
          -  Understand the trial and have signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have graft-versus-host disease (GVHD) or need to use immunosuppressive&#xD;
             agents&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and&#xD;
             peripheral blood HBV DNA titer test is not within the normal reference range;&#xD;
             hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human&#xD;
             immunodeficiency virus (HIV) Antibody positive; CMV DNA test positive; Syphilis test&#xD;
             positive&#xD;
&#xD;
          -  Severe heart disease&#xD;
&#xD;
          -  Systemic diseases judged by the investigator to be unstable: including but not limited&#xD;
             to severe liver, kidney or metabolic diseases that require medication&#xD;
&#xD;
          -  Within 7 days before screening, there are active infections or uncontrollable&#xD;
             infections that require systemic treatment (except for mild urogenital infections and&#xD;
             upper respiratory tract infections)&#xD;
&#xD;
          -  Those who have received CAR-T therapy or other genetically modified cell therapy&#xD;
             before screening&#xD;
&#xD;
          -  According to the researcher's judgment, it does not meet the situation of cell&#xD;
             preparation&#xD;
&#xD;
          -  Situations that other researchers think are not suitable for inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ShaoYan Hu</last_name>
    <phone>137-7187-0462</phone>
    <email>hushaoyan@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HuiMin Meng</last_name>
    <phone>188-9680-2149</phone>
    <email>huimin.meng@persongen.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chilren's Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ShaoYan Hu</last_name>
      <phone>137-7187-0462</phone>
      <email>hushaoyan@suda.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>HuiMin Meng</last_name>
      <phone>188-9680-2149</phone>
      <email>huimin.meng@persongen.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

